ACR vs AXR

ACR exhibits weak financial health with a Piotroski F-Score of just 2/9, signaling significant operational and balance sheet concerns. Despite strong recent earnings growth and profitability margins, the company's high leverage (Debt/Equity of 2.84) and extremely low valuation multiples like Price/Book of 0.32 suggest deep underlying risks. The absence of an Altman Z-Score due to insufficient data further clouds solvency assessment, while technical indicators and insider sentiment are neutral-to-bearish. Although the stock appears undervalued relative to the Graham Number ($35.84) and analyst target ($24.50), erratic earnings surprises and lack of dividend support undermine confidence in sustained recovery.

The company exhibits weak fundamental health with a Piotroski F-Score of 3/9, indicating significant financial distress risks. Despite strong profitability margins and a debt-free balance sheet, the business is experiencing sharp declines in revenue and earnings, with YoY earnings down 70.7%. The stock trades below its Graham Number of $33.48 but at a premium to its growth-adjusted intrinsic value of $13.51, suggesting overvaluation given deteriorating fundamentals. Persistent negative earnings surprises and lack of analyst coverage further undermine confidence.